Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer
Dr. Maltzman Brings Oncology and Autoimmune Experience in All Stages of Drug Development, from Early-Stage Research to Successful Regulatory Approvals and Commercialization Press Release – December 18, 2024 – REDWOOD CITY, Calif. & BOSTON – Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Julie … Continue reading Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer